Targeting the cancer glycocalyx in salivary duct carcinoma: tumor‐associated mucin 1 (Tn‐ MUC1 ) as a novel cell surface marker
The Journal of Pathology: Clinical Research · 2025
DOI: 10.1002/2056-4538.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Masashi Kuroki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Mucin-1, Biomarkers, Tumor, Glycocalyx. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Despite the use of targeted drugs for human epidermal growth factor receptor type 2 (HER2)‐positive salivary duct carcinoma (SDC) treatment, the overall prognosis for SDC remains poor. In this study, we aimed to investigate whether the glycocalyx of SDC cells serves as a potential cell surface marker. To understand the complex structure of the glycocalyx of salivary gland tumors, we used a lectin with glycan‐specific binding properties. Lectin staining was performed for five types of common salivary gland tumors. We determined the expression of the transmembrane glycoprotein mucin 1 with Tn antigen (GalNAc), Tn‐MUC1, using 20 clinical SDC specimens. Vicia villosa lectin (VVL) was not stained in the vascular endothelium but specifically stained in the SDC tumor cells. GalNAc, to which VVL binds, formed Tn‐MUC1 via glycosylation with N‐acetylgalactosaminyltransferases (GALNTs). GALNT7 was highly expressed in SDC. Analysis of clinical SDC specimens revealed that Tn‐MUC1 was also positive in the SDC tumor cells, suggesting its potential as a cell surface target for SDC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
- Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan.
- Department of Head and Neck Surgery-Otorhinolaryngology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
ORCID-Profile: Ryo Kawaura, Hirofumi Shibata
Förderung
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
Zitieren
APA
Kuroki, M., Kawaura, R., Tomita, H., Shibata, H., Ohashi, T., Ishikawa, T., Okada, H., Hara, A., & Ogawa, T. (2025). Targeting the cancer glycocalyx in salivary duct carcinoma: tumor‐associated mucin 1 (Tn‐ MUC1 ) as a novel cell surface marker. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70042
Vancouver
Kuroki M, Kawaura R, Tomita H, Shibata H, Ohashi T, Ishikawa T, et al. Targeting the cancer glycocalyx in salivary duct carcinoma: tumor‐associated mucin 1 (Tn‐ MUC1 ) as a novel cell surface marker. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70042
BibTeX
@article{Kuroki2025,
author = {Kuroki, Masashi and Kawaura, Ryo and Tomita, Hiroyuki and Shibata, Hirofumi and Ohashi, Toshimitsu and Ishikawa, Tomohiko and Okada, Hideshi and Hara, Akira and Ogawa, Takenori},
title = {Targeting the cancer glycocalyx in salivary duct carcinoma: tumor‐associated mucin 1 (Tn‐ MUC1 ) as a novel cell surface marker},
journal = {The Journal of Pathology: Clinical Research},
year = {2025},
doi = {10.1002/2056-4538.70042}
}
EUVIMED